WO2020258585A1 - Health food for improvement of female fertility and preparation method thereof - Google Patents
Health food for improvement of female fertility and preparation method thereof Download PDFInfo
- Publication number
- WO2020258585A1 WO2020258585A1 PCT/CN2019/110573 CN2019110573W WO2020258585A1 WO 2020258585 A1 WO2020258585 A1 WO 2020258585A1 CN 2019110573 W CN2019110573 W CN 2019110573W WO 2020258585 A1 WO2020258585 A1 WO 2020258585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- powder
- parts
- health food
- haematococcus pluvialis
- peptide powder
- Prior art date
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 40
- 230000035558 fertility Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 25
- 230000006872 improvement Effects 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 126
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 35
- 102000008186 Collagen Human genes 0.000 claims abstract description 27
- 108010035532 Collagen Proteins 0.000 claims abstract description 27
- 229920001436 collagen Polymers 0.000 claims abstract description 27
- 241000133134 Saussurea Species 0.000 claims abstract description 19
- 235000021552 granulated sugar Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 235000013601 eggs Nutrition 0.000 claims description 25
- 240000002853 Nelumbo nucifera Species 0.000 claims description 17
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 17
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241001336827 Rana chensinensis Species 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 235000010439 isomalt Nutrition 0.000 claims description 6
- 239000000905 isomalt Substances 0.000 claims description 6
- -1 isomalt oligosaccharide Chemical class 0.000 claims description 6
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 4
- 108090000145 Bacillolysin Proteins 0.000 claims description 4
- 108091005658 Basic proteases Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108091005507 Neutral proteases Proteins 0.000 claims description 4
- 102000035092 Neutral proteases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 241000276707 Tilapia Species 0.000 claims description 4
- 235000013793 astaxanthin Nutrition 0.000 claims description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 4
- 229940022405 astaxanthin Drugs 0.000 claims description 4
- 239000001168 astaxanthin Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 241000269435 Rana <genus> Species 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000191896 Rana sylvatica Species 0.000 abstract description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 abstract description 7
- 241000700159 Rattus Species 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
- 206010046798 Uterine leiomyoma Diseases 0.000 description 8
- 201000010260 leiomyoma Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 208000007984 Female Infertility Diseases 0.000 description 6
- 206010021928 Infertility female Diseases 0.000 description 6
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000186 progesterone Substances 0.000 description 6
- 229960003387 progesterone Drugs 0.000 description 6
- 240000000950 Hippophae rhamnoides Species 0.000 description 5
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000020230 cinnamon extract Nutrition 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 244000241872 Lycium chinense Species 0.000 description 3
- 235000015468 Lycium chinense Nutrition 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008956 guizhi-fuling Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 235000017784 Mespilus germanica Nutrition 0.000 description 2
- 244000182216 Mimusops elengi Species 0.000 description 2
- 235000000560 Mimusops elengi Nutrition 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000011707 Ovulation disease Diseases 0.000 description 2
- 235000007837 Vangueria infausta Nutrition 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000529 abnormal spermatogenesis Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000002434 celiac artery Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention belongs to the technical field of biological products, and specifically relates to a health food for improving female fertility and a preparation method thereof.
- infertility In recent years, the incidence of infertility has increased significantly, which has attracted great attention from all walks of life. The causes of infertility are divided into male infertility and female infertility. In 1992, the World Health Organization used this classification most widely in the diagnosis and treatment of infertility. The primary cause of diagnosis is in order: ovulation disorders, semen abnormalities, fallopian tube abnormalities, unexplained infertility, endometriosis and other such as immunological infertility. Another factor is cervical factors, including cervical stenosis which accounts for more than 5% of all cervical factors. Female infertility is mainly caused by ovulation disorders, fallopian tube factors, and abnormal endometrial receptivity. Male infertility is mainly caused by abnormal spermatogenesis and dysregulation.
- the Chinese patent "CN201710140768, a health food suitable for women” provides a health food or nutritional supplement composed of vitamin E, folic acid, vitamin B12 and appropriate auxiliary materials, in which vitamin E The content is 10-00mg, folic acid content is 0.2-2.0mg, vitamin B12 content is 5-100 ⁇ g.
- This health food claims to have beauty and anti-aging effects, and has auxiliary protective effects on the reproductive health of women of childbearing age and the cardiovascular health of middle-aged and elderly women;
- the effective components of the health food are vitamin E, folic acid, and vitamin B12, and its components are more focused on drugs, and the effect on the reproductive function of women of childbearing age is not obvious.
- the present invention provides a health food for improving women's fertility function and a preparation method thereof.
- the health food can prevent and treat uterine fibroids, increase SOD value and delay aging, and help women's fertility function. Recovery and promotion.
- a health food for improving female fertility characterized in that, the health food comprises the following raw materials: Haematococcus pluvialis powder, Rana rana egg peptide powder, collagen peptide powder, white granulated sugar powder, oligoisomaltose powder, Snow lotus culture.
- the health food is prepared from the following raw materials in parts by weight: 8-15 parts of Haematococcus pluvialis powder, 10-15 parts of Rana chensinensis egg peptide powder, 10-15 parts of collagen peptide powder, 35-45 parts Parts of white granulated sugar powder, 8-12 parts of isomalt oligosaccharide powder, 2-4 parts of snow lotus culture.
- the health food is prepared from the following raw materials in parts by weight: 10 parts of Haematococcus pluvialis powder, 10 parts of wood frog egg peptide powder, 15 parts of collagen peptide powder, 40 parts of white sugar powder, 10 parts of low Polyisomaltose powder, 3 parts of snow lotus culture.
- the preparation method of the health food comprises the following steps: mixing Haematococcus pluvialis powder, Rana rana ovata powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus extract evenly, and drying , Sub-package, that is.
- the preparation method of the Haematococcus pluvialis powder includes the following steps: drying Haematococcus pluvialis, pulverizing, and passing through a 100-mesh sieve to obtain it.
- the preparation method of Rana chensinensis egg peptide powder includes the following steps:
- the preparation method of the Saussurea culture includes the following steps:
- Saussurea Tianshanensis was vacuum-dried to constant weight at 40°C, then crushed, and passed through a 100-mesh sieve to obtain a Saussurea culture.
- the preparation method of the collagen peptide powder includes the following steps:
- the water content of the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, and isomalt oligosaccharide powder are all less than 4%.
- the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
- the beneficial effects of the present invention mainly include but are not limited to the following aspects:
- the present invention removes some Chinese medicine components, avoids the safety hazards caused by excessive Chinese medicine components, and can also avoid production stagnation due to the shortage of some Chinese medicine materials; the present invention passes Reasonable compatibility of various components can significantly reduce the uterine coefficient of uterine fibroids model rats; the health food of the present invention has a significant inhibitory effect on the hormone content in the blood of rats, and this inhibitory effect hinders to a certain extent
- the hyperplasia and hypertrophy of uterine myalgia significantly reduce the weight of the uterus of the model rat and reduce the uterine coefficient; the measurement of other blood indexes shows that the health food of the present invention can also increase the SOD value and has an anti-aging effect.
- Saussurea culture is rich in flavonoids, polysaccharides, phenolic acids and other functional components. The quality is uniform and stable, without the bitterness and odor of wild plants. It is more suitable for human digestion and absorption. Saussurea culture replaces other Chinese herbal medicine extracts. In addition, it is compatible with Haematococcus pluvialis powder, Rana chensinensis egg peptide powder and collagen peptide powder to help restore female fertility, prevent and treat uterine fibroids, which is a significant improvement over the prior art.
- a health food for improving female fertility including the following raw materials prepared by weight: 10 parts of Haematococcus pluvialis powder, 10 parts of Rana sylvatica powder, 15 parts of collagen peptide powder, 40 parts of white sugar powder, 10 parts of isomalt oligosaccharide powder, 3 parts of snow lotus culture.
- the water content of the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus culture is less than 4%.
- the preparation method of the health food includes the following steps:
- Haematococcus pluvialis powder Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus extract evenly, dry, and pack.
- the preparation method of the Haematococcus pluvialis powder includes the following steps:
- the Haematococcus pluvialis is dried, crushed, and passed through a 100-mesh sieve to obtain; the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
- the preparation method of the forest frog egg peptide powder includes the following steps:
- the preparation method of the snow lotus culture includes the following steps:
- the method for obtaining the callus of Saussurea Tianshanensis is referred to "Study on Callus Culture and Formation of Secondary Receptors of Saussurea Tianshanensis, Research and Information on Traditional Chinese Medicine, 2005", and other methods commonly used in the field can also be referred to.
- the preparation method of the collagen peptide powder includes the following steps:
- a health food for improving female fertility including the following raw materials by weight: 8 parts of Haematococcus pluvialis powder, 12 parts of Rana sylvatica powder, 12 parts of collagen peptide powder, 38 parts of white sugar powder, 8 parts of isomalt oligosaccharide powder, 2 parts of snow lotus culture.
- the water content of the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus culture is less than 4%.
- the preparation method of the health food includes the following steps:
- Haematococcus pluvialis powder Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus extract evenly, dry, and pack.
- the preparation method of the Haematococcus pluvialis powder includes the following steps:
- the Haematococcus pluvialis is dried, crushed, and passed through a 100-mesh sieve to obtain; the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
- the preparation method of the forest frog egg peptide powder includes the following steps:
- the preparation method of the snow lotus culture includes the following steps:
- the method for obtaining the callus of Saussurea Tianshanensis is referred to "Study on Callus Culture and Formation of Secondary Receptors of Saussurea Tianshanensis, Research and Information on Traditional Chinese Medicine, 2005", and other methods commonly used in the field can also be referred to.
- the preparation method of the collagen peptide powder includes the following steps:
- a functional food for improving female infertility comprising the following raw materials by weight: 10 parts of Haematococcus pluvialis powder, 10 parts of Rana sylvatica powder, 5 parts of wolfberry extract, 5 parts of cinnamon Extract, 5 parts of sea buckthorn extract, 15 parts of collagen peptide powder, 40 parts of white granulated sugar powder, 10 parts of oligoisomaltose powder, 3 parts of cane fruit oil, 0.5 parts of food flavor.
- the relative densities of the wolfberry extract, cinnamon extract and sea-buckthorn extract were all 1.20 at 80°C.
- the water content of polyisomaltose powder is less than 4%.
- the method for preparing the above functional food includes the following steps:
- Step 1 After selecting sea buckthorn, medlar and cinnamon, heat reflux and extract for 4 hours.
- the extract is filtered to remove impurities, and concentrated to 80°C.
- the extract has a relative density of 1.20 for use.
- Step 2 Combine Haematococcus pluvialis powder, Rana sylvatica egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder, cane fruit oil, food flavor, medlar extract, cinnamon extract, sea buckthorn The extract is evenly mixed, dried, and packed.
- Experimental animals 70 healthy adult SD rats, clean grade, weighing 180-220g. Give complete nutrient solid feed, eat and drink freely, control the room temperature at 25°C, and have lighting and ventilation conditions.
- experimental group is according to Example 1 of the present invention
- control group 1 estradiol standard product (100 mg/bottle), progesterone standard product (20 mg/bottle) (Shanghai Yuanye Biotechnology Co., Ltd.)
- control group 2 Gui Zhifuling Capsules (Kangyuan Pharmaceutical).
- Dose and grouping According to the random number method, they are divided into blank control group, model group, control group 1, control group 2, and experimental group of low-dose, medium-dose, and high-dose groups.
- the blank control group and the model group were infused with physiological saline 10ml/kg every day, and the control group 2 (Guizhi Fuling capsule group, adult dosage is 0.31g/capsule, three capsules each time, three times a day) according to 50kg body weight adults and rats
- the equivalent amount of body surface area is equivalent to 6.3 times that of an adult; 0.38g/kg is the total crude drug amount for each rat in this group, and the total daily gavage volume of each rat is calculated by the standard of 10ml/kg.
- the total crude drug was dissolved in normal saline; the control group 1 chose the dose of 0.38g/kg (the same dose as the experimental group).
- the experimental group of the present invention is the low-dose group (0.19g/kg), which is equivalent to 0.5 times the clinical dose; the medium-dose group (0.38g/kg), which is equivalent to the clinical dose; the high-dose group (0.76g/kg), which is equivalent to the clinical dose 2 times the dose.
- the model was given by intragastric administration at the same time, once a day, for 8 consecutive weeks. Rats in each group were anesthetized and sacrificed at the 8th week after the intervention of intragastric administration, and related tests were performed.
- Modeling After one week of adaptive feeding, the rat is intraperitoneally injected with benzoic acid glycol injection 0.5mg/kg for 25 days, and then changed to intraperitoneal injection of progesterone injection 4mg/kg for 5 days to establish a uterine fibroids model .
- the blank control group was left untreated.
- Biological sample collection 24 hours after the last medication, all rats were weighed and recorded, and then anesthetized by intraperitoneal injection of isoamtobarbital sodium, blood was collected from the celiac artery, and the blood was centrifuged at 2500r/min for 15 minutes and then the serum was taken out and placed in the refrigerator spare. After blood sampling, the rats were sacrificed. The general shape of the uterus was observed by laparotomy, the uterus was cut, weighed and recorded, and the uterine coefficient was calculated by uterine weight/body weight (mg/g). After the weighing is completed, the uterus is fixed in a 10% neutral formaldehyde solution.
- the uterine coefficient of the model group was significantly higher than that of the blank control group, indicating that the model was successful.
- the medium-dose uterine coefficient decreased significantly, and the low-dose uterine coefficient also decreased;
- the experimental group medium-dose group can significantly reduce the rat uterine coefficient;
- This experiment uses intraperitoneal injection of estradiol and progesterone to increase the weight of the rat's uterus and obtain a model of uterine fibroids.
- the model group Compared with the blank control group, the model group has significant differences in hormones and uterine weight gain, indicating that the model is successful; other blood indicators also confirm the success of the model from the side, such as uterine fibroids can cause triglycerides and total cholesterol
- the content of triglyceride and total cholesterol in the model group was significantly higher than that of the blank control group.
- the health food of the present invention has a significant reduction effect on the E2 and P content of model rats in the low-dose and medium-dose groups, indicating that it has a significant inhibitory effect on the hormone content in the blood of rats, and this inhibitory effect hinders the development of uterine myalgia Hyperplasia and hypertrophy changes, thereby significantly reducing the weight of the uterus of the model rats and reducing the uterine coefficient.
- the superoxide dismutase (SOD) values of the control group 1-2 and the experimental group were significantly higher than those of the blank control group. Among them, the increase in the medium and high doses of the experimental group was more obvious, indicating that the The invented health food can also increase the SOD value and have anti-aging effects.
- the embodiment of the present invention improves the health product composition, removes part of the traditional Chinese medicine components, avoids the safety hazards caused by excessive Chinese medicine components, and can also avoid the production stagnation caused by the shortage of some traditional Chinese medicine materials; A reasonable combination of these components can significantly reduce the uterine coefficient of uterine fibroids model rats; the health food of the present invention has a significant inhibitory effect on the hormone content in the blood of rats, and this inhibitory effect hinders the uterine muscle to a certain extent.
- the hyperplasia and hypertrophy changes of the pain, thereby significantly reducing the weight of the uterus of the model rat, and reducing the uterine coefficient; other blood index measurement shows that the health food of the present invention can also increase the SOD value and has an anti-aging effect.
- Saussurea culture is rich in flavonoids, polysaccharides, phenolic acids and other functional components. The quality is uniform and stable, without the bitterness and odor of wild plants. It is more suitable for human digestion and absorption. Saussurea culture replaces other Chinese herbal medicine extracts. In addition, it is compatible with Haematococcus pluvialis powder, Rana chensinensis egg peptide powder and collagen peptide powder to help restore female fertility, prevent and treat uterine fibroids, which is a significant improvement over the prior art.
Abstract
A health food for improvement of female fertility, containing the following raw materials: haematococcus pluvialis, wood frog spawn peptide powder, collagen peptide powder, white granulated sugar powder, isomalto-oligosaccharide powder and saussurea involucrate culture.
Description
本申请要求于2019年06月27日提交中国专利局、申请号为201910568442.9、申请名称为“用于提高女性生育机能的保健食品及其制备方法”的专利申请的优先权,其全部内容通过引用结合在本申请中。This application claims the priority of a patent application filed with the Chinese Patent Office on June 27, 2019, the application number is 201910568442.9, and the application title is "health food for improving female fertility and its preparation method", the entire content of which is incorporated by reference Incorporated in this application.
本发明属于生物制品技术领域,具体涉及用于提高女性生育机能的保健食品及其制备方法。The invention belongs to the technical field of biological products, and specifically relates to a health food for improving female fertility and a preparation method thereof.
近年来,不孕不育的发生率大幅提高,引起了社会各界的高度重视。引起不孕的发病原因分为男性不孕和女性不孕,1992年被世界卫生组织在诊断和治疗不孕症最广泛应用该分类。首要的病因诊断依次是:排卵障碍、精液异常、输卵管异常、不明原因的不孕、子宫内膜异位症和其他如免疫学不孕。另外因素是宫颈因素,包括占所有宫颈因素超过5%的宫颈狭窄。女性不孕主要以排卵障碍,输卵管因素,子宫内膜容受性异常为主,男性不孕主要是生精异常及排精障碍。In recent years, the incidence of infertility has increased significantly, which has attracted great attention from all walks of life. The causes of infertility are divided into male infertility and female infertility. In 1992, the World Health Organization used this classification most widely in the diagnosis and treatment of infertility. The primary cause of diagnosis is in order: ovulation disorders, semen abnormalities, fallopian tube abnormalities, unexplained infertility, endometriosis and other such as immunological infertility. Another factor is cervical factors, including cervical stenosis which accounts for more than 5% of all cervical factors. Female infertility is mainly caused by ovulation disorders, fallopian tube factors, and abnormal endometrial receptivity. Male infertility is mainly caused by abnormal spermatogenesis and dysregulation.
引起女性不孕不育的一个重要因素是卵巢和子宫机能的衰退。现有技术关于提高女性生育机能的保健食品较多,包括申请人之前的专利技术“CN201711391586,一种改善女性不孕不育的功能性食品及其制备方法”,公开了一种改善女性不孕不育的功能性食品,其特征在于:包括如下重量份的原料制备而成:5-15份雨生红球藻粉、5-15份林蛙卵肽粉、2-8份枸杞子浸膏、2-8份肉桂浸膏、2-8份沙棘浸膏、10-20份胶原蛋白肽粉、30-45份白砂糖粉、5-15份低聚异麦芽糖粉、1-5份美藤果油、0.2-0.8份食用香精”,该组合物采用发酵、酶解、纯化、喷雾干燥、热回流提取等技术,配方合理,能够增加基础窦卵泡,提升卵巢功能,改善子宫容受性,提升自然受孕及试管婴儿成功率。中 国专利“CN201710140768,一种适用于女性的保健食品”提供了一种由维生素E、叶酸、维生素B12及适当辅料组成的保健食品或营养补充剂,其中维生素E含量为10-00mg、叶酸含量为0.2-2.0mg、维生素B12含量为5-100μg。该保健食品声称具有美容抗衰老效果,对育龄女性生殖健康以及对中老年女性心血管健康有辅助保护作用;但是该保健食品的有效组分为维生素E、叶酸、维生素B12,其组分更偏重于药物,对育龄妇女的生育机能作用的改善并不明显。An important factor that causes female infertility is the decline of ovarian and uterine functions. There are many health foods for improving female fertility in the prior art, including the applicant’s previous patent technology "CN201711391586, a functional food for improving female infertility and its preparation method", which discloses a method for improving female infertility A sterile functional food, characterized in that it comprises the following raw materials prepared by weight: 5-15 parts of Haematococcus pluvialis powder, 5-15 parts of Rana sylvatica powder, 2-8 parts of Chinese wolfberry extract , 2-8 parts of cinnamon extract, 2-8 parts of sea buckthorn extract, 10-20 parts of collagen peptide powder, 30-45 parts of white sugar powder, 5-15 parts of oligoisomaltose powder, 1-5 parts of Mito Fruit oil, 0.2-0.8 servings of edible flavor", the composition adopts fermentation, enzymatic hydrolysis, purification, spray drying, heat reflux extraction and other technologies, and has a reasonable formula, which can increase basal antral follicles, enhance ovarian function, and improve uterine receptivity. Improve the success rate of natural conception and IVF. The Chinese patent "CN201710140768, a health food suitable for women" provides a health food or nutritional supplement composed of vitamin E, folic acid, vitamin B12 and appropriate auxiliary materials, in which vitamin E The content is 10-00mg, folic acid content is 0.2-2.0mg, vitamin B12 content is 5-100μg. This health food claims to have beauty and anti-aging effects, and has auxiliary protective effects on the reproductive health of women of childbearing age and the cardiovascular health of middle-aged and elderly women; However, the effective components of the health food are vitamin E, folic acid, and vitamin B12, and its components are more focused on drugs, and the effect on the reproductive function of women of childbearing age is not obvious.
实用新型内容Utility model content
为了克服现有技术的缺陷,本发明提供了用于提高女性生育机能的保健食品及其制备方法,该保健食品能够预防和治疗子宫肌瘤,提高SOD值延缓衰老,有助于女性生育机能的恢复和提升。In order to overcome the shortcomings of the prior art, the present invention provides a health food for improving women's fertility function and a preparation method thereof. The health food can prevent and treat uterine fibroids, increase SOD value and delay aging, and help women's fertility function. Recovery and promotion.
本发明是通过如下技术方案来实现的:The present invention is realized through the following technical solutions:
用于提高女性生育机能的保健食品,其特征在于,所述保健食品包括如下原料:雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉、雪莲培养物。A health food for improving female fertility, characterized in that, the health food comprises the following raw materials: Haematococcus pluvialis powder, Rana rana egg peptide powder, collagen peptide powder, white granulated sugar powder, oligoisomaltose powder, Snow lotus culture.
进一步地,所述保健食品由如下重量份的原料制备而成:8-15份雨生红球藻粉、10-15份林蛙卵肽粉、10-15份胶原蛋白肽粉、35-45份白砂糖粉、8-12份低聚异麦芽糖粉、2-4份雪莲培养物。Further, the health food is prepared from the following raw materials in parts by weight: 8-15 parts of Haematococcus pluvialis powder, 10-15 parts of Rana chensinensis egg peptide powder, 10-15 parts of collagen peptide powder, 35-45 parts Parts of white granulated sugar powder, 8-12 parts of isomalt oligosaccharide powder, 2-4 parts of snow lotus culture.
进一步地,所述保健食品由如下重量份的原料制备而成:10份雨生红球藻粉、10份林蛙卵肽粉、15份胶原蛋白肽粉、40份白砂糖粉、10份低聚异麦芽糖粉、3份雪莲培养物。Further, the health food is prepared from the following raw materials in parts by weight: 10 parts of Haematococcus pluvialis powder, 10 parts of wood frog egg peptide powder, 15 parts of collagen peptide powder, 40 parts of white sugar powder, 10 parts of low Polyisomaltose powder, 3 parts of snow lotus culture.
优选地,所述保健食品的制备方法包括如下步骤:将雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲提取物混合均匀,干燥,分装,即得。Preferably, the preparation method of the health food comprises the following steps: mixing Haematococcus pluvialis powder, Rana rana ovata powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus extract evenly, and drying , Sub-package, that is.
优选地,所述雨生红球藻粉的制备方法包括如下步骤:将雨生红球藻干燥,粉碎,过100目筛,即得。Preferably, the preparation method of the Haematococcus pluvialis powder includes the following steps: drying Haematococcus pluvialis, pulverizing, and passing through a 100-mesh sieve to obtain it.
优选地,所述林蛙卵肽粉的制备方法包括如下步骤:Preferably, the preparation method of Rana chensinensis egg peptide powder includes the following steps:
将除油后的雪蛤卵加入到蒸馏水中,调节pH值,加入2000U/g的碱性蛋白酶,60℃恒温水浴水解120min,90℃水浴加热10min,冷却至室温,调pH值至中性,7000r/min离心10min,取上清液浓缩、干燥、粉碎,过100目筛,即得。Add the degreasing snow clam eggs to distilled water, adjust the pH value, add 2000U/g alkaline protease, hydrolyze in a constant temperature water bath at 60°C for 120 minutes, heat in a water bath at 90°C for 10 minutes, cool to room temperature, adjust the pH value to neutral, 7000r Centrifuge for 10 min at /min, take the supernatant, concentrate, dry, pulverize, and pass through a 100-mesh sieve to get it.
优选地,所述雪莲培养物的制备方法包括如下步骤:Preferably, the preparation method of the Saussurea culture includes the following steps:
将天山雪莲愈伤组织置于40℃真空干燥至恒重,然后粉碎,过100目筛,得到雪莲培养物。The callus of Saussurea Tianshanensis was vacuum-dried to constant weight at 40°C, then crushed, and passed through a 100-mesh sieve to obtain a Saussurea culture.
优选地,所述胶原蛋白肽粉的制备方法包括如下步骤:Preferably, the preparation method of the collagen peptide powder includes the following steps:
将罗非鱼皮和浓度为0.1M的氢氧化钠溶液按照1:5的料液比(w/v)混合,然后升温至90℃,保温1h,降温至50℃,然后调整pH为7.0,再添加中性蛋白酶和风味蛋白酶,添加量分别为1000U/ml和300U/ml,酶解3h,95℃灭酶5min,然后采用孔径为0.45微米的微孔滤膜过滤,收集滤过液,再通过截留分子量为3000Da的超滤膜进行超滤,收集滤过液,减压浓缩,最后喷雾干燥制得。Mix tilapia skin and 0.1M sodium hydroxide solution according to the material-to-liquid ratio (w/v) of 1:5, then heat up to 90°C, keep it for 1h, cool down to 50°C, and then adjust the pH to 7.0. Then add neutral protease and flavour protease in the dosages of 1000U/ml and 300U/ml respectively, enzymolyze for 3h, inactivate the enzyme at 95℃ for 5min, then filter with a 0.45 micron microporous membrane, collect the filtrate, and then Ultrafiltration is performed through an ultrafiltration membrane with a molecular weight cut-off of 3000Da, the filtrate is collected, concentrated under reduced pressure, and finally spray-dried.
优选地,所述雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉的含水率均小于4%。Preferably, the water content of the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, and isomalt oligosaccharide powder are all less than 4%.
优选地,所述雨生红球藻粉的虾青素含量为1.8-2.2%。Preferably, the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
与现有技术相比较,本发明的有益效果主要包括但是并不限于以下几个方面:Compared with the prior art, the beneficial effects of the present invention mainly include but are not limited to the following aspects:
本发明通过对申请人之前的保健品组合物进行改进,去除了部分中药组分,避免了中药组分过多造成的安全隐患,同样能够避免因为部分中药材短缺造成的生产停滞;本发明通过对各种组分进行合理配伍,能够显著降低子宫肌瘤模型大鼠的子宫系数;本发明保健食品对大鼠血液中激素的含量有明显的抑制作用,这种抑制作用在一定程度上阻碍了子宫肌痛的增生肥大变化,从而明显减轻了模型大鼠的子宫重量,降低了子宫系数;其他血液指标测定表明本发明保健食品还可提高S0D值,具有抗衰老的效果。By improving the applicant’s previous health care product composition, the present invention removes some Chinese medicine components, avoids the safety hazards caused by excessive Chinese medicine components, and can also avoid production stagnation due to the shortage of some Chinese medicine materials; the present invention passes Reasonable compatibility of various components can significantly reduce the uterine coefficient of uterine fibroids model rats; the health food of the present invention has a significant inhibitory effect on the hormone content in the blood of rats, and this inhibitory effect hinders to a certain extent The hyperplasia and hypertrophy of uterine myalgia significantly reduce the weight of the uterus of the model rat and reduce the uterine coefficient; the measurement of other blood indexes shows that the health food of the present invention can also increase the SOD value and has an anti-aging effect.
雪莲培养物含有丰富的黄酮类、多糖类、酚酸类等功效性成分,品质均一稳定,无野生植物的苦涩和气味,更适合人体消化吸收,将雪莲培养物替代其 他中药材提取物,并且与雨生红球藻粉、林蛙卵肽粉以及胶原蛋白肽粉进行配伍,有助于恢复女性生育机能,预防和治疗子宫肌瘤,较现有技术有明显提升。Saussurea culture is rich in flavonoids, polysaccharides, phenolic acids and other functional components. The quality is uniform and stable, without the bitterness and odor of wild plants. It is more suitable for human digestion and absorption. Saussurea culture replaces other Chinese herbal medicine extracts. In addition, it is compatible with Haematococcus pluvialis powder, Rana chensinensis egg peptide powder and collagen peptide powder to help restore female fertility, prevent and treat uterine fibroids, which is a significant improvement over the prior art.
为了使本技术领域的人员更好地理解本申请中的技术方案,下面将结合本申请具体实施例,对本发明进行更加清楚、完整地描述,显然,所描述的实施例仅仅是本申请一部分实施例,而不是全部的实施例。基于本申请中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。In order to enable those skilled in the art to better understand the technical solutions in this application, the following will describe the present invention more clearly and completely in conjunction with specific embodiments of this application. Obviously, the described embodiments are only part of the implementation of this application. Examples, not all examples. Based on the embodiments in this application, all other embodiments obtained by those of ordinary skill in the art without creative work should fall within the protection scope of the present invention.
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。The experimental methods used in the following examples are conventional methods unless otherwise specified.
下述实施例中所使用的原料,如无特殊说明,均可从商业途径得到。The raw materials used in the following examples can be obtained from commercial sources unless otherwise specified.
实施例1Example 1
用于提高女性生育机能的保健食品,包括如下重量份的原料制备而成:10份雨生红球藻粉、10份林蛙卵肽粉、15份胶原蛋白肽粉、40份白砂糖粉、10份低聚异麦芽糖粉、3份雪莲培养物。A health food for improving female fertility, including the following raw materials prepared by weight: 10 parts of Haematococcus pluvialis powder, 10 parts of Rana sylvatica powder, 15 parts of collagen peptide powder, 40 parts of white sugar powder, 10 parts of isomalt oligosaccharide powder, 3 parts of snow lotus culture.
所述雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲培养物的含水率均小于4%。The water content of the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus culture is less than 4%.
所述保健食品的制备方法,包括如下步骤:The preparation method of the health food includes the following steps:
将雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲提取物混合均匀,干燥,分装。Mix Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus extract evenly, dry, and pack.
所述雨生红球藻粉的制备方法包括如下步骤:The preparation method of the Haematococcus pluvialis powder includes the following steps:
将雨生红球藻干燥,粉碎,过100目筛,即得;所述雨生红球藻粉的虾青素含量为1.8-2.2%。The Haematococcus pluvialis is dried, crushed, and passed through a 100-mesh sieve to obtain; the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
所述林蛙卵肽粉的制备方法包括如下步骤:The preparation method of the forest frog egg peptide powder includes the following steps:
将除油后的雪蛤卵加入到蒸馏水中,调节pH值,加入2000U/g的碱性蛋白酶,60℃恒温水浴水解120min,90℃水浴加热10min,冷却至室温,调pH值至中性,7000r/min离心10min,取上清液浓缩、干燥、粉碎,过100目筛, 即得;Add the degreasing snow clam eggs to distilled water, adjust the pH value, add 2000U/g alkaline protease, hydrolyze in a constant temperature water bath at 60°C for 120 minutes, heat in a water bath at 90°C for 10 minutes, cool to room temperature, adjust the pH value to neutral, 7000r Centrifuge for 10 min at /min, take the supernatant, concentrate, dry, crush, and pass through a 100-mesh sieve to get it;
所述雪莲培养物的制备方法包括如下步骤:The preparation method of the snow lotus culture includes the following steps:
将天山雪莲愈伤组织置于40℃真空干燥至恒重,然后粉碎,过100目筛,得到雪莲培养物;Put the callus of Tianshan Saussurea in vacuum drying at 40°C to constant weight, then pulverize, pass through a 100-mesh sieve to obtain a Saussurea culture;
所述天山雪莲愈伤组织的获取方法参照“天山雪莲愈伤组织培养与次生答谢物形成的研究,中药研究与信息,2005年”,也可以参照本领域常用的其他方法。The method for obtaining the callus of Saussurea Tianshanensis is referred to "Study on Callus Culture and Formation of Secondary Receptors of Saussurea Tianshanensis, Research and Information on Traditional Chinese Medicine, 2005", and other methods commonly used in the field can also be referred to.
所述胶原蛋白肽粉的制备方法包括如下步骤:The preparation method of the collagen peptide powder includes the following steps:
将罗非鱼皮和浓度为0.1M的氢氧化钠溶液按照1:5的料液比(w/v)混合,然后升温至90℃,保温1h,降温至50℃,然后调整pH为7.0,再添加中性蛋白酶和风味蛋白酶,添加量分别为1000U/ml和300U/ml,酶解3h,95℃灭酶5min,然后采用孔径为0.45微米的微孔滤膜过滤,收集滤过液,再通过截留分子量为3000Da的超滤膜进行超滤,收集滤过液,减压浓缩,最后喷雾干燥制得。Mix tilapia skin and 0.1M sodium hydroxide solution according to the material-to-liquid ratio (w/v) of 1:5, then heat up to 90°C, keep it for 1h, cool down to 50°C, and then adjust the pH to 7.0. Then add neutral protease and flavour protease in the dosages of 1000U/ml and 300U/ml respectively, enzymolyze for 3h, inactivate the enzyme at 95℃ for 5min, then filter with a 0.45 micron microporous membrane, collect the filtrate, and then Ultrafiltration is performed through an ultrafiltration membrane with a molecular weight cut-off of 3000Da, the filtrate is collected, concentrated under reduced pressure, and finally spray-dried.
实施例2Example 2
用于提高女性生育机能的保健食品,包括如下重量份的原料制备而成:8份雨生红球藻粉、12份林蛙卵肽粉、12份胶原蛋白肽粉、38份白砂糖粉、8份低聚异麦芽糖粉、2份雪莲培养物。A health food for improving female fertility, including the following raw materials by weight: 8 parts of Haematococcus pluvialis powder, 12 parts of Rana sylvatica powder, 12 parts of collagen peptide powder, 38 parts of white sugar powder, 8 parts of isomalt oligosaccharide powder, 2 parts of snow lotus culture.
所述雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲培养物的含水率均小于4%。The water content of the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus culture is less than 4%.
所述保健食品的制备方法,包括如下步骤:The preparation method of the health food includes the following steps:
将雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲提取物混合均匀,干燥,分装。Mix Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder and snow lotus extract evenly, dry, and pack.
所述雨生红球藻粉的制备方法包括如下步骤:The preparation method of the Haematococcus pluvialis powder includes the following steps:
将雨生红球藻干燥,粉碎,过100目筛,即得;所述雨生红球藻粉的虾青素含量为1.8-2.2%。The Haematococcus pluvialis is dried, crushed, and passed through a 100-mesh sieve to obtain; the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
所述林蛙卵肽粉的制备方法包括如下步骤:The preparation method of the forest frog egg peptide powder includes the following steps:
将除油后的雪蛤卵加入到蒸馏水中,调节pH值,加入2000U/g的碱性蛋 白酶,60℃恒温水浴水解120min,90℃水浴加热10min,冷却至室温,调pH值至中性,7000r/min离心10min,取上清液浓缩、干燥、粉碎,过100目筛,即得;Add the degreasing snow clam eggs to distilled water, adjust the pH value, add 2000U/g alkaline protease, hydrolyze in a constant temperature water bath at 60°C for 120 minutes, heat in a water bath at 90°C for 10 minutes, cool to room temperature, adjust the pH value to neutral, 7000r Centrifuge for 10 min at /min, take the supernatant, concentrate, dry, crush, and pass through a 100-mesh sieve to get it;
所述雪莲培养物的制备方法包括如下步骤:The preparation method of the snow lotus culture includes the following steps:
将天山雪莲愈伤组织置于40℃真空干燥至恒重,然后粉碎,过100目筛,得到雪莲培养物;Put the callus of Tianshan Saussurea in vacuum drying at 40°C to constant weight, then pulverize, pass through a 100-mesh sieve to obtain a Saussurea culture;
所述天山雪莲愈伤组织的获取方法参照“天山雪莲愈伤组织培养与次生答谢物形成的研究,中药研究与信息,2005年”,也可以参照本领域常用的其他方法。The method for obtaining the callus of Saussurea Tianshanensis is referred to "Study on Callus Culture and Formation of Secondary Receptors of Saussurea Tianshanensis, Research and Information on Traditional Chinese Medicine, 2005", and other methods commonly used in the field can also be referred to.
所述胶原蛋白肽粉的制备方法包括如下步骤:The preparation method of the collagen peptide powder includes the following steps:
将罗非鱼皮和0.1M的氢氧化钠溶液按照1:5的料液比(w/v)混合,然后升温至90℃,保温1h,降温至50℃,然后调整pH为7.0,再添加中性蛋白酶和风味蛋白酶,添加量分别为1000U/ml和300U/ml,酶解3h,95℃灭酶5min,然后采用孔径为0.45微米的微孔滤膜过滤,收集滤过液,再通过截留分子量为3000Da的超滤膜进行超滤,收集滤过液,减压浓缩,最后喷雾干燥制得。Mix tilapia skin and 0.1M sodium hydroxide solution according to the material-to-liquid ratio (w/v) of 1:5, then heat up to 90°C, keep it for 1h, cool down to 50°C, adjust the pH to 7.0, and add Neutral protease and flavor protease, add 1000U/ml and 300U/ml respectively, enzymolyse for 3h, inactivate the enzyme at 95℃ for 5min, then filter with a 0.45 micron microporous membrane, collect the filtrate, and pass it The ultrafiltration membrane with a molecular weight of 3000Da is subjected to ultrafiltration, the filtrate is collected, concentrated under reduced pressure, and finally obtained by spray drying.
对照组1Control group 1
参照CN201711391586。Refer to CN201711391586.
一种改善女性不孕不育的功能性食品,包括如下重量份的原料制备而成:10份雨生红球藻粉、10份林蛙卵肽粉、5份枸杞子浸膏、5份肉桂浸膏、5份沙棘浸膏、15份胶原蛋白肽粉、40份白砂糖粉、10份低聚异麦芽糖粉、3份美藤果油、0.5份食用香精。A functional food for improving female infertility, comprising the following raw materials by weight: 10 parts of Haematococcus pluvialis powder, 10 parts of Rana sylvatica powder, 5 parts of wolfberry extract, 5 parts of cinnamon Extract, 5 parts of sea buckthorn extract, 15 parts of collagen peptide powder, 40 parts of white granulated sugar powder, 10 parts of oligoisomaltose powder, 3 parts of cane fruit oil, 0.5 parts of food flavor.
所述枸杞子浸膏、肉桂浸膏和沙棘浸膏在80℃热测相对密度均为1.20,所述雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉的含水率均小于4%。The relative densities of the wolfberry extract, cinnamon extract and sea-buckthorn extract were all 1.20 at 80°C. The Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, low The water content of polyisomaltose powder is less than 4%.
上述功能性食品的制备方法包括如下步骤:The method for preparing the above functional food includes the following steps:
步骤一、将沙棘、枸杞子、肉桂经挑选后热回流提取4小时,提取液过滤除杂,浓缩至80℃热测相对密度为1.20的浸膏备用;Step 1. After selecting sea buckthorn, medlar and cinnamon, heat reflux and extract for 4 hours. The extract is filtered to remove impurities, and concentrated to 80°C. The extract has a relative density of 1.20 for use.
步骤二、将雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉、美藤果油、食用香精、枸杞子浸膏、肉桂浸膏、沙棘浸膏混合均匀,干燥,分装。Step 2: Combine Haematococcus pluvialis powder, Rana sylvatica egg peptide powder, collagen peptide powder, white granulated sugar powder, oligomeric isomaltose powder, cane fruit oil, food flavor, medlar extract, cinnamon extract, sea buckthorn The extract is evenly mixed, dried, and packed.
实施例3Example 3
动物实验Animal experiment
实验动物:健康成年SD大鼠70只,清洁级,体重180-220g。给予全营养固体饲料,自由摄食饮水,室温控制在25℃,采光通风条件。Experimental animals: 70 healthy adult SD rats, clean grade, weighing 180-220g. Give complete nutrient solid feed, eat and drink freely, control the room temperature at 25°C, and have lighting and ventilation conditions.
药物:实验组为本发明实施例1;对照组1;雌二醇标准品(lOOmg/瓶),黄体酮标准品(20mg/瓶)(上海源叶生物科技有限公司),对照组2:桂枝茯苓胶囊(康缘药业)。Drugs: experimental group is according to Example 1 of the present invention; control group 1; estradiol standard product (100 mg/bottle), progesterone standard product (20 mg/bottle) (Shanghai Yuanye Biotechnology Co., Ltd.), control group 2: Gui Zhifuling Capsules (Kangyuan Pharmaceutical).
剂量与分组:按随机数字法分为空白对照组,模型组,对照1组,对照2组,实验组的小剂量、中剂量、大剂量组。空白对照组和模型组每日灌以生理盐水10ml/kg,对照组2(桂枝茯苓胶囊组,成人用量为0.31g/粒,每次三粒,每日三次)按照50kg体重成人与大鼠体表面积折算的等效量相当于成人的6.3倍;0.38g/kg为该组每只大鼠总生药量以10ml/kg的标准计算出每只大鼠每日灌胃总体积,以此体积的生理盐水溶解总生药;对照组1选择剂量0.38g/kg(和实验组中剂量相同)。本发明实验组小剂量组(0.19g/kg),相当于临床剂量的0.5倍;中剂量组(0.38g/kg),相当于临床剂量;高剂量组(0.76g/kg),相当于临床剂量的2倍。造模同时灌胃给药,1次/d,连续8周。各组大鼠于灌胃给药干预后第8周分别麻醉处死动物,进行相关检测。Dose and grouping: According to the random number method, they are divided into blank control group, model group, control group 1, control group 2, and experimental group of low-dose, medium-dose, and high-dose groups. The blank control group and the model group were infused with physiological saline 10ml/kg every day, and the control group 2 (Guizhi Fuling capsule group, adult dosage is 0.31g/capsule, three capsules each time, three times a day) according to 50kg body weight adults and rats The equivalent amount of body surface area is equivalent to 6.3 times that of an adult; 0.38g/kg is the total crude drug amount for each rat in this group, and the total daily gavage volume of each rat is calculated by the standard of 10ml/kg. The total crude drug was dissolved in normal saline; the control group 1 chose the dose of 0.38g/kg (the same dose as the experimental group). The experimental group of the present invention is the low-dose group (0.19g/kg), which is equivalent to 0.5 times the clinical dose; the medium-dose group (0.38g/kg), which is equivalent to the clinical dose; the high-dose group (0.76g/kg), which is equivalent to the clinical dose 2 times the dose. The model was given by intragastric administration at the same time, once a day, for 8 consecutive weeks. Rats in each group were anesthetized and sacrificed at the 8th week after the intervention of intragastric administration, and related tests were performed.
造模:大鼠适应性喂养一周后,腹腔注射苯甲酸二醇注射液0.5mg/kg,连续25d,后改为腹腔注射黄体酮注射液4mg/kg,连5d,即可建立子宫肌瘤模型。空白对照组不作处理。Modeling: After one week of adaptive feeding, the rat is intraperitoneally injected with benzoic acid glycol injection 0.5mg/kg for 25 days, and then changed to intraperitoneal injection of progesterone injection 4mg/kg for 5 days to establish a uterine fibroids model . The blank control group was left untreated.
生物样本取材:末次用药后24h将所有大鼠称重并记录,然后腹腔注射异戊巴比妥钠麻醉,腹腔动脉取血,血液以2500r/min,冷冻离心15min后取出血清,置于冰箱中备用。取血后处死大鼠,剖腹先观察子宫大体形状,剪子宫,称重并记录,以子宫重量/体重(mg/g)计算子宫系数。称重完毕后,将子宫固 定于10%中性甲醛溶液中。Biological sample collection: 24 hours after the last medication, all rats were weighed and recorded, and then anesthetized by intraperitoneal injection of isoamtobarbital sodium, blood was collected from the celiac artery, and the blood was centrifuged at 2500r/min for 15 minutes and then the serum was taken out and placed in the refrigerator spare. After blood sampling, the rats were sacrificed. The general shape of the uterus was observed by laparotomy, the uterus was cut, weighed and recorded, and the uterine coefficient was calculated by uterine weight/body weight (mg/g). After the weighing is completed, the uterus is fixed in a 10% neutral formaldehyde solution.
血清中雌激素、孕激素的含量测定:Determination of estrogen and progesterone in serum:
于第四周时大鼠眼眶取血,血液以2500r/min,冷冻离心15min后,取出血清,用于测量雌二醇(E2)和孕酮(P)。At the fourth week, blood was taken from the orbit of the rat. The blood was centrifuged at 2500 r/min for 15 minutes, and then the serum was taken out to measure estradiol (E2) and progesterone (P).
实验结果Experimental results
对大鼠子宫重量的影响见表1。The effect on the weight of the rat uterus is shown in Table 1.
表1Table 1
与模型组比较#P<0.05,##P<0.01,与空白对照组比较*P<0.05,**P<0.01Compared with the model group #P<0.05, ##P<0.01, compared with the blank control group *P<0.05, **P<0.01
如表1所示,与空白对照组比较,模型组子宫系数明显高于空白对照组,说明造模成功。与模型组比较,中剂量子宫系数明显下降,小剂量子宫系数也有降低;通过与对照组1-2相比较,实验组中剂量组能够明显降低大鼠子宫系数;说明本发明通过对于对照组1的组方的改进,功效有了较大的提升,也优于现有技术常用的桂枝茯苓胶囊。As shown in Table 1, compared with the blank control group, the uterine coefficient of the model group was significantly higher than that of the blank control group, indicating that the model was successful. Compared with the model group, the medium-dose uterine coefficient decreased significantly, and the low-dose uterine coefficient also decreased; compared with the control group 1-2, the experimental group medium-dose group can significantly reduce the rat uterine coefficient; With the improvement of the formula, the efficacy has been greatly improved, and it is also better than the Guizhi Fuling capsule commonly used in the prior art.
表2各组别对大鼠雌孕激素的影响(4周)Table 2 Effects of each group on estrogen and progesterone in rats (4 weeks)
与模型组比较#P<0.05,##P<0.01,与空白对照组比较*P<0.05,**P<0.01Compared with the model group #P<0.05, ##P<0.01, compared with the blank control group *P<0.05, **P<0.01
如表2所示,第四周检测结果,与空白对照组比较,模型组血清E2、P值均明显升高。与模型组比较,实验组的中剂量组和高剂量组血淸E2均下降明显,具备极其显著性差异,对照组1具备显著性差异。与模型组比较,对照组1-2,实验组的小剂量组均下降明显,具备显著性差异,实验组中剂量组血淸E2具备极其显著性差异。As shown in Table 2, in the fourth week of the test results, compared with the blank control group, the serum E2 and P values of the model group were significantly increased. Compared with the model group, the blood E2 of the middle-dose group and the high-dose group of the experimental group decreased significantly, with extremely significant difference, and the control group 1 had a significant difference. Compared with the model group, both the control group 1-2 and the experimental group's low-dose group decreased significantly, with significant differences, and the experimental group's medium-dose group's blood E2 had extremely significant differences.
结论:本实验采用腹腔注射雌二醇和孕酮的方法,造成大鼠子宫重量增加,得到子宫肌瘤模型。与空白对照组比较,模型组在激素及子宫增重方面均有显著性差异,说明造模成功;其他血液指标也从侧面证实了模型的成功,如子宫肌瘤可以导致甘油三酯和总胆固醇的上调,本实验中,甘油三酯和总胆固醇在模型组的含量明显高于空白对照组。本发明保健食品在小剂量、中剂量组对模型大鼠的E2、P含量有显著降低作用,表明对大鼠血液中激素的含量有明显的抑制作用,这种抑制作用阻碍了子宫肌痛的增生肥大变化,从而明显减轻了模型大鼠的子宫重量,降低了子宫系数。其他血液指标测定中,对照组1-2和实验组各剂量组超氧化物歧化酶(S0D)值均显著高于空白对照组,其中,实验组中剂量和大剂量的增幅更明显,表明本发明保健食品还可提高S0D值,具有抗衰老的效果。Conclusion: This experiment uses intraperitoneal injection of estradiol and progesterone to increase the weight of the rat's uterus and obtain a model of uterine fibroids. Compared with the blank control group, the model group has significant differences in hormones and uterine weight gain, indicating that the model is successful; other blood indicators also confirm the success of the model from the side, such as uterine fibroids can cause triglycerides and total cholesterol In this experiment, the content of triglyceride and total cholesterol in the model group was significantly higher than that of the blank control group. The health food of the present invention has a significant reduction effect on the E2 and P content of model rats in the low-dose and medium-dose groups, indicating that it has a significant inhibitory effect on the hormone content in the blood of rats, and this inhibitory effect hinders the development of uterine myalgia Hyperplasia and hypertrophy changes, thereby significantly reducing the weight of the uterus of the model rats and reducing the uterine coefficient. In the determination of other blood indicators, the superoxide dismutase (SOD) values of the control group 1-2 and the experimental group were significantly higher than those of the blank control group. Among them, the increase in the medium and high doses of the experimental group was more obvious, indicating that the The invented health food can also increase the SOD value and have anti-aging effects.
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。Although the general description, specific embodiments and tests have been used to describe the present invention in detail, some modifications or improvements can be made on the basis of the present invention, which is obvious to those skilled in the art. . Therefore, these modifications or improvements made without departing from the spirit of the present invention belong to the scope of the present invention.
本发明实施例通过对保健品组合物进行改进,去除了部分中药组分,避免了中药组分过多造成的安全隐患,同样能够避免因为部分中药材短缺造成的生产停滞;本发明通过对各种组分进行合理配伍,能够显著降低子宫肌瘤模型大鼠的子宫系数;本发明保健食品对大鼠血液中激素的含量有明显的抑制作用,这种抑制作用在一定程度上阻碍了子宫肌痛的增生肥大变化,从而明显减轻了模型大鼠的子宫重量,降低了子宫系数;其他血液指标测定表明本发明保健食品还可提高S0D值,具有抗衰老的效果。雪莲培养物含有丰富的黄酮类、多糖类、酚酸类等功效性成分,品质均一稳定,无野生植物的苦涩和气味,更适合人体消化吸收,将雪莲培养物替代其他中药材提取物,并且与雨生红球藻粉、林蛙卵肽粉以及胶原蛋白肽粉进行配伍,有助于恢复女性生育机能,预防和治疗子宫肌瘤,较现有技术有明显提升。The embodiment of the present invention improves the health product composition, removes part of the traditional Chinese medicine components, avoids the safety hazards caused by excessive Chinese medicine components, and can also avoid the production stagnation caused by the shortage of some traditional Chinese medicine materials; A reasonable combination of these components can significantly reduce the uterine coefficient of uterine fibroids model rats; the health food of the present invention has a significant inhibitory effect on the hormone content in the blood of rats, and this inhibitory effect hinders the uterine muscle to a certain extent. The hyperplasia and hypertrophy changes of the pain, thereby significantly reducing the weight of the uterus of the model rat, and reducing the uterine coefficient; other blood index measurement shows that the health food of the present invention can also increase the SOD value and has an anti-aging effect. Saussurea culture is rich in flavonoids, polysaccharides, phenolic acids and other functional components. The quality is uniform and stable, without the bitterness and odor of wild plants. It is more suitable for human digestion and absorption. Saussurea culture replaces other Chinese herbal medicine extracts. In addition, it is compatible with Haematococcus pluvialis powder, Rana chensinensis egg peptide powder and collagen peptide powder to help restore female fertility, prevent and treat uterine fibroids, which is a significant improvement over the prior art.
Claims (10)
- 用于提高女性生育机能的保健食品,其特征在于,所述保健食品包括如下原料:雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉、雪莲培养物。A health food for improving female fertility, characterized in that, the health food comprises the following raw materials: Haematococcus pluvialis powder, Rana rana egg peptide powder, collagen peptide powder, white granulated sugar powder, oligoisomaltose powder, Snow lotus culture.
- 根据权利要求1所述的保健食品,其特征在于,所述保健食品由如下重量份的原料制备而成:8-15份雨生红球藻粉、10-15份林蛙卵肽粉、10-15份胶原蛋白肽粉、35-45份白砂糖粉、8-12份低聚异麦芽糖粉、2-4份雪莲培养物。The health food according to claim 1, wherein the health food is prepared from the following raw materials by weight: 8-15 parts of Haematococcus pluvialis powder, 10-15 parts of Rana chensinensis egg peptide powder, 10 parts -15 parts of collagen peptide powder, 35-45 parts of white granulated sugar powder, 8-12 parts of oligoisomaltose powder, 2-4 parts of snow lotus culture.
- 根据权利要求2所述的保健食品,其特征在于,所述保健食品由如下重量份的原料制备而成:10份雨生红球藻粉、10份林蛙卵肽粉、15份胶原蛋白肽粉、40份白砂糖粉、10份低聚异麦芽糖粉、3份雪莲培养物。The health food according to claim 2, wherein the health food is prepared from the following parts by weight of raw materials: 10 parts of Haematococcus pluvialis powder, 10 parts of Rana chensinensis egg peptide powder, 15 parts of collagen peptide Powder, 40 parts white granulated sugar powder, 10 parts isomalt oligosaccharide powder, 3 parts snow lotus culture.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述保健食品的制备方法包括如下步骤:将雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲提取物混合均匀,干燥,分装,即得。The health food according to any one of claims 1-3, wherein the preparation method of the health food comprises the following steps: mixing Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white Granulated sugar powder, isomalt oligosaccharide powder and snow lotus extract are mixed uniformly, dried, and packed, and then get.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述雨生红球藻粉的制备方法包括如下步骤:将雨生红球藻干燥,粉碎,过100目筛,即得。The health food according to any one of claims 1 to 3, wherein the preparation method of Haematococcus pluvialis powder comprises the following steps: drying Haematococcus pluvialis, crushing, and passing through a 100-mesh sieve, namely Got.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述林蛙卵肽粉的制备方法包括如下步骤:将除油后的雪蛤卵加入到蒸馏水中,调节pH值,加入碱性蛋白酶,添加量未2000U/g,60℃水解120min,90℃水浴加热10min,冷却至室温,调pH值至中性,7000r/min离心10min,取上清液浓缩、干燥、粉碎,过100目筛,即得。The health food according to any one of claims 1 to 3, wherein the preparation method of Rana chensinensis egg peptide powder comprises the following steps: adding the deoiled snow clam eggs into distilled water, adjusting the pH value, and adding Alkaline protease, add 2000U/g, hydrolyze at 60℃ for 120min, heat in water bath at 90℃ for 10min, cool to room temperature, adjust pH to neutral, centrifuge at 7000r/min for 10min, take the supernatant, concentrate, dry, crush, A 100 mesh sieve is ready.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述雪莲培养物的制备方法包括如下步骤:将天山雪莲愈伤组织置于40℃真空干燥至恒重,然后粉碎,过100目筛,得到雪莲培养物。The health food according to any one of claims 1 to 3, wherein the preparation method of the Saussurea praecox culture comprises the following steps: drying the callus of Tianshan Saussurea in vacuum at 40°C to a constant weight, and then crushing. Pass a 100-mesh sieve to obtain a Saussurea culture.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述胶原蛋白肽粉的制备方法包括如下步骤:将罗非鱼皮和浓度为0.1M的氢氧化钠溶液按照1:5的料液比(w/v)混合,然后升温至90℃,保温1h,降温至50℃,然后调整pH为7.0,再添加中性蛋白酶和风味蛋白酶,添加量分别为1000U/ml和300U/ml,酶解3h,95℃灭酶5min,然后采用孔径为0.45微米的微孔滤膜过滤,收集滤过液,再通过截留分子量为3000Da的超滤膜进行超滤,收集滤过液,减压浓缩,最后喷雾干燥制得。The health food according to any one of claims 1 to 3, wherein the preparation method of the collagen peptide powder comprises the following steps: the tilapia skin and a 0.1M sodium hydroxide solution according to 1: 5, mix with the material-to-liquid ratio (w/v), then increase the temperature to 90℃, keep it for 1h, cool to 50℃, then adjust the pH to 7.0, and then add neutral protease and flavor protease, the addition amount is 1000U/ml and 300U respectively /ml, enzymatic hydrolysis for 3h, inactivate the enzyme at 95°C for 5min, then filter with a 0.45 micron microporous filter to collect the filtrate, and then ultrafiltration through an ultrafiltration membrane with a molecular weight cut-off of 3000Da to collect the filtrate. Concentrated under reduced pressure, and finally produced by spray drying.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述雨生红球藻粉、林蛙卵肽粉、胶原蛋白肽粉、白砂糖粉、低聚异麦芽糖粉以及雪莲培养物的含水率均小于4%。The health food according to any one of claims 1 to 3, wherein the Haematococcus pluvialis powder, Rana chensinensis egg peptide powder, collagen peptide powder, white granulated sugar powder, oligoisomaltose powder and snow lotus The water content of the cultures is less than 4%.
- 根据权利要求1-3任其一所述的保健食品,其特征在于,所述雨生红球藻粉的虾青素含量为1.8-2.2%。The health food according to any one of claims 1 to 3, wherein the astaxanthin content of the Haematococcus pluvialis powder is 1.8-2.2%.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910568442.9A CN110200282A (en) | 2019-06-27 | 2019-06-27 | For improving the health food and preparation method thereof of female fertility function |
CN201910568442.9 | 2019-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020258585A1 true WO2020258585A1 (en) | 2020-12-30 |
Family
ID=67795043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/110573 WO2020258585A1 (en) | 2019-06-27 | 2019-10-11 | Health food for improvement of female fertility and preparation method thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110200282A (en) |
WO (1) | WO2020258585A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110964798A (en) * | 2020-03-05 | 2020-04-07 | 东北农业大学 | Method for identifying northeast wood frog genetic sex by using TRAP molecular marker technology |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110200282A (en) * | 2019-06-27 | 2019-09-06 | 杭州妇帮医疗科技有限公司 | For improving the health food and preparation method thereof of female fertility function |
CN113502315B (en) * | 2021-07-29 | 2023-03-31 | 广东海洋大学 | Tilapia skin peptide, preparation method thereof and application thereof in improving premature ovarian failure |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103918966A (en) * | 2013-01-15 | 2014-07-16 | 北京同仁堂健康药业股份有限公司 | Composition containing Haematococcus pluvialis |
CN104413416A (en) * | 2013-08-21 | 2015-03-18 | 董人源 | Formula of snowfrog and astaxanthin compound capsules produced from snowfrog oil and production process |
CN107951019A (en) * | 2017-12-21 | 2018-04-24 | 杭州妇帮医疗科技有限公司 | A kind of functional food for improving female infertility and preparation method thereof |
CN109832536A (en) * | 2018-09-28 | 2019-06-04 | 北京姿美堂生物技术有限公司 | A kind of taste collagen solid beverage and preparation method thereof |
CN110200282A (en) * | 2019-06-27 | 2019-09-06 | 杭州妇帮医疗科技有限公司 | For improving the health food and preparation method thereof of female fertility function |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512669B (en) * | 2011-12-13 | 2013-06-26 | 北京同仁堂健康药业股份有限公司 | Female whitening skin-nourishing composition |
CN106031721B (en) * | 2015-03-11 | 2020-02-21 | 上海瑞亦康生物科技有限公司 | Composition containing extract of astaxanthin and use thereof |
CN106387891B (en) * | 2016-09-18 | 2019-12-24 | 大连普瑞康生物技术有限公司 | Saussurea involucrata culture ginseng nutrition powder and preparation method thereof |
CN106360696B (en) * | 2016-09-18 | 2019-12-24 | 大连普瑞康生物技术有限公司 | A food composition containing saussurea involucrata culture and nidus Collocaliae |
CN109010622A (en) * | 2018-11-01 | 2018-12-18 | 河南五极中医药研究院 | Nest Chinese medicine composition and preparation method thereof is supported in the menstruation regulating of integration of drinking and medicinal herbs |
-
2019
- 2019-06-27 CN CN201910568442.9A patent/CN110200282A/en not_active Withdrawn
- 2019-10-11 WO PCT/CN2019/110573 patent/WO2020258585A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103918966A (en) * | 2013-01-15 | 2014-07-16 | 北京同仁堂健康药业股份有限公司 | Composition containing Haematococcus pluvialis |
CN104413416A (en) * | 2013-08-21 | 2015-03-18 | 董人源 | Formula of snowfrog and astaxanthin compound capsules produced from snowfrog oil and production process |
CN107951019A (en) * | 2017-12-21 | 2018-04-24 | 杭州妇帮医疗科技有限公司 | A kind of functional food for improving female infertility and preparation method thereof |
CN109832536A (en) * | 2018-09-28 | 2019-06-04 | 北京姿美堂生物技术有限公司 | A kind of taste collagen solid beverage and preparation method thereof |
CN110200282A (en) * | 2019-06-27 | 2019-09-06 | 杭州妇帮医疗科技有限公司 | For improving the health food and preparation method thereof of female fertility function |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110964798A (en) * | 2020-03-05 | 2020-04-07 | 东北农业大学 | Method for identifying northeast wood frog genetic sex by using TRAP molecular marker technology |
CN110964798B (en) * | 2020-03-05 | 2023-07-07 | 东北农业大学 | Method for identifying genetic sex of rana chensinensis by using TRAP molecular marker technology |
Also Published As
Publication number | Publication date |
---|---|
CN110200282A (en) | 2019-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020258585A1 (en) | Health food for improvement of female fertility and preparation method thereof | |
CN102697035A (en) | Cordyceps anti-aging pellet | |
CN108434248B (en) | Extraction method and application of active ingredients of medlar | |
KR20070094394A (en) | A composition comprising medical herbs for infertility | |
US10675316B2 (en) | Composition for preventing and treating climacteric disorder containing extracts of Dendropanax morbifera LEV. as active ingredient | |
CN109601795A (en) | Using penthorum chinense pursh as composition alcohol-decomposing beverage of primary raw material and preparation method thereof | |
CN107752005A (en) | A kind of pilose antler double enzymolysis extracting method | |
EP1718167A1 (en) | Composition comprising hovenia dulcis thunb. extract, lindera obtusiloba blume extract, or herbal mixture extract thereof | |
JP7160901B2 (en) | Composition for use in treating and/or preventing infertility | |
CN109275778A (en) | A kind of women helps pregnant food formula of special diet and preparation method thereof | |
CN109481670A (en) | A kind of composition that can be relieved insomnia and improve sleep quality | |
CN112273656A (en) | Black garlic oral liquid capable of enhancing immunity and preparation method thereof | |
JP3628999B2 (en) | Anonymous tea and its manufacturing method | |
KR102080410B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts | |
KR20150051597A (en) | Food Composition for improving liver function containing extract of Arctiumlappa L. | |
KR101626938B1 (en) | Composition for Preventing or Improving Precocious Puberty | |
KR101730949B1 (en) | Compositions for preventing or treating infertility comprising an extract of Perilla frutescens | |
CN109453267A (en) | Sobering-up composition and the preparation method and application thereof | |
KR20200048459A (en) | Preparation manufacturing of composition for the improving of respiratory disease comprising pear and citron, and composition prepared thereby | |
CN106727902B (en) | Cordyceps sinensis-containing traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver and application thereof | |
KR20160121023A (en) | Composition containing paeoniflorin for preventing or treating infertility | |
KR101088711B1 (en) | A composition for prevention or alleviation of obesity containing Astragalus membranaceus extract manufactured by using enzymatic hydrolysis | |
JP7352275B2 (en) | Composition for improving menopausal symptoms | |
WO2018072276A1 (en) | Health-care food and preparation method therefor | |
CN110214955B (en) | Composition with function of nourishing ovaries and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19935100 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19935100 Country of ref document: EP Kind code of ref document: A1 |